


PRODUCT INFORMATION



Sugammadex (sodium salt)

Item No. 24096

CAS Registry No.: 343306-79-6
Formal Name: 6^A,6^B,6^C,6^D,6^E,6^F,6^G,6^H-octakis-S-(2-carboxyethyl)-6^A,6^B,6^C,6^D,6^E,6^F,6^G,6^H-octathio- γ -cyclodextrin, octosodium salt
Synonym: ORG 25969
MF: C₇₂H₁₀₄O₄₈S₈ • 8Na
FW: 2,178.0
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Sugammadex (sodium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the sugammadex (sodium salt) in the solvent of choice, which should be purged with an inert gas. Sugammadex (sodium salt) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of sugammadex (sodium salt) in these solvents is approximately 2.5 mg/ml.

Sugammadex (sodium salt) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, sugammadex (sodium salt) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Sugammadex (sodium salt) has a solubility of approximately 0.03 mg/ml in a 1:30 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Sugammadex is a synthetic derivative of γ -cyclodextrin and a steroid-based neuromuscular blocker reversing agent.¹ It binds rocuronium (Item No. 23698) within its cyclodextrin ring and selectively reverses rocuronium-induced neuromuscular blockade over that induced by mivacurium (Item No. 23610) or atracurium (Item No. 17796) in anesthetized rhesus monkeys. Sugammadex also prevents formation of postoperative peritoneal adhesions in rats.² In a rat model of ischemia-reperfusion injury, sugammadex (16 and 100 mg/kg) increases the total number of neurons in the hippocampus compared to control and improves motor coordination in a beam walking test.³

References

1. de Boer, H.D., van Egmond, J., van de Pol, F., *et al.* Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. *Br. J. Anaesth.* **96(4)**, 473-479 (2006).
2. Şahin, H., Toman, H., Kiraz, H.A., *et al.* Effects of sugammadex on the prevention of postoperative peritoneal adhesions. *Kaohsiung J. Med. Sci.* **31(9)**, 463-467 (2015).
3. Ozbilgin, S., Yilmaz, O., Ergur, B.U., *et al.* Effectiveness of sugammadex for cerebral ischemia/reperfusion injury. *Kaohsiung, J. Med. Sci.* **32(6)**, 292-301 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM